MML Investors Services LLC Boosts Holdings in Avantor, Inc. (NYSE:AVTR)

MML Investors Services LLC raised its holdings in shares of Avantor, Inc. (NYSE:AVTR) by 7.4% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 50,793 shares of the company’s stock after purchasing an additional 3,492 shares during the period. MML Investors Services LLC’s holdings in Avantor were worth $1,314,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. SG Americas Securities LLC grew its holdings in shares of Avantor by 222.0% during the second quarter. SG Americas Securities LLC now owns 19,996 shares of the company’s stock worth $424,000 after buying an additional 13,786 shares in the last quarter. Wealth Enhancement Advisory Services LLC grew its holdings in shares of Avantor by 2.8% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 26,921 shares of the company’s stock worth $571,000 after buying an additional 733 shares in the last quarter. Assenagon Asset Management S.A. grew its holdings in shares of Avantor by 403.4% during the second quarter. Assenagon Asset Management S.A. now owns 133,515 shares of the company’s stock worth $2,831,000 after buying an additional 106,992 shares in the last quarter. Blue Trust Inc. grew its holdings in shares of Avantor by 1,830.3% during the second quarter. Blue Trust Inc. now owns 1,467 shares of the company’s stock worth $31,000 after buying an additional 1,391 shares in the last quarter. Finally, Van Lanschot Kempen Investment Management N.V. grew its holdings in shares of Avantor by 16.7% during the second quarter. Van Lanschot Kempen Investment Management N.V. now owns 2,902,290 shares of the company’s stock worth $61,529,000 after buying an additional 416,342 shares in the last quarter. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

AVTR has been the subject of a number of recent research reports. Royal Bank of Canada reiterated an “outperform” rating and set a $34.00 price target on shares of Avantor in a report on Thursday, September 26th. Barclays decreased their target price on shares of Avantor from $28.00 to $25.00 and set an “overweight” rating on the stock in a research report on Friday, October 25th. UBS Group decreased their target price on shares of Avantor from $30.00 to $29.00 and set a “buy” rating on the stock in a research report on Tuesday, October 8th. Wells Fargo & Company decreased their target price on shares of Avantor from $30.00 to $28.00 and set an “overweight” rating on the stock in a research report on Monday, October 28th. Finally, Robert W. Baird decreased their target price on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating on the stock in a research report on Monday, October 28th. Two investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Avantor currently has a consensus rating of “Moderate Buy” and a consensus price target of $27.69.

Avantor Trading Down 4.0 %

Shares of AVTR stock opened at $21.11 on Thursday. The stock has a market cap of $14.37 billion, a price-to-earnings ratio of 45.89, a price-to-earnings-growth ratio of 2.75 and a beta of 1.29. The company has a quick ratio of 1.06, a current ratio of 1.54 and a debt-to-equity ratio of 0.84. Avantor, Inc. has a fifty-two week low of $19.59 and a fifty-two week high of $28.00. The firm’s 50 day moving average price is $22.29 and its two-hundred day moving average price is $23.49.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.